Press Releases
Jul 10, 2023
Cytox CEO, Dr. Richard Pither, Talks About genoSCORE™-ACT Genetic Risk Test for Alzheimer's Disease on the UK's Only Dementia-Focussed Radio Show – ‘The 'D' Word With Pete Hill'
Jun 1, 2023
Cytox brings ground-breaking genetic risk test for Alzheimer's disease to the UK
Dec 1, 2022
Cytox welcomes momentous and historic news for Alzheimer’s disease research – the dawn of a new therapeutic age?
Nov 21, 2022
First Choice Neurology tests first patients with the Alzheimer’s Risk Test
Sep 15, 2022
Cytox and Thermo Fisher Scientific collaboration highlights the potential of predictive genomics to enable pre-emptive healthcare
Jul 26, 2022
Launch of First Direct to Consumer Social Media Awareness Campaign for the Alzheimer’s Risk Test
May 4, 2022
Research shows link between Alzheimer’s disease and lifestyle and wellbeing
Sep 21, 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of the first, physician use only, polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
Jul 26, 2021
Cytox strengthens management team to support commercialisation of genoSCORE test to predict risk of cognitive decline due to Alzheimer’s disease
Jul 16, 2021
Cytox appoints BERBĒS as market developer in Spain, to introduce a new test that predicts the risk of cognitive decline due to Alzheimer’s disease
Jun 23, 2021
Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s disease
Jun 8, 2021
Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease
Feb 24, 2021
Cytox launches genoSCORE-LAB test to predict the risk of developing Alzheimer’s disease
Nov 17, 2020
Cytox publishes research showing its genoSCORE-LAB test can predict the risk of cognitive decline due to Alzheimer’s disease without invasive procedures
Sep 2, 2020
Cytox signs licence agreement with Cardiff University for polygenic risk score technology that is key to development of lead product genoSCORE(TM)
Jun 5, 2020
ESHG 2020 : Cyotx will be presenting Polygenic risk scores analysis for Alzheimer’s Disease; transforming early detection and clinical management
Jul 17, 2019
Cytox presents poster at AAIC 2019 on predicting an individual’s risk of developing Alzheimer's Disease
Jul 14, 2019
Cytox and Cardiff University present poster at AAIC 2019 on the genetics of Alzheimer’s Disease in populations with different ancestries
Apr 1, 2019
View the latest discussion from Professor Valentina Escott-Price on polygenic risk score analysis and genomic profiling in Alzheimer’s disease
Mar 13, 2019
Cardiff University and Cytox to present further results on the implementation of SNPfitR analytical platform in identifying individuals for Alzheimer’s clinical trials at AD/PD conference in Lisbon
Feb 28, 2019
Cytox White Paper on assessing Alzheimer’s disease risk using polygenic risk scoring biomarkers updated following validation by new study
Oct 19, 2018
Cytox to present research on polygenic risk score application to stratification of risk for Alzheimer’s Disease at 13th International Conference on Genomics in Shenzhen, China.
Oct 18, 2018
Cytox, Cardiff University and University of Birmingham to present research on application of polygenic risk score (PRS) analysis to stratification of subjects for clinical trials in Alzheimer’s disease in carriers and non-carriers of the ApoE4 risk allele
Oct 11, 2018
Cardiff University and Cytox to present research showing polygenic risk score approach predicts Alzheimer’s Disease and mild cognitive impairment better than APOE in ADNI dataset
Sep 24, 2018
Cytox expands collaboration with AIBL to identify those most at risk to rapidly progress to Alzheimer’s
Jul 18, 2018
Cytox White Paper now available on Assessing Alzheimer’s disease risk using polygenic risk scoring biomarkers
May 22, 2018
Cytox launches collaboration agreement with Mayo Clinic to evaluate novel genetic based approaches for assessing Alzheimer’s risk
May 8, 2018
Cytox in collaboration with AKESOgen extends genetic test for assessing Alzheimer's disease risk to include saliva samples
Mar 7, 2018
Cytox congratulates Professor John Hardy and his fellow winners of this year’s €1m Brain Prize
Nov 2, 2017
New precision medicine approach for assessing Alzheimer’s disease risk presented at CTAD conference in Boston
Jun 15, 2017
Cytox raises £2.6m led by Catapult Ventures to launch predictive testing service for Alzheimer’s disease
Mar 20, 2017
Breakthrough studies describing new precision medicine approach for assessing Alzheimer’s disease risk to be presented at AD/PD conference in Vienna
Dec 1, 2016
Cytox presentations on studies with breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment at CTAD 2016
Jul 24, 2016
Cytox launches interpretive software for breakthrough genetic biomarker research assay for Alzheimer’s risk assessment at AAIC
Jul 22, 2016
Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s disease risk assessment
Nov 10, 2015
Cytox congratulates Professor John Hardy, first UK winner of $3m Breakthrough Prize in Life Sciences
Nov 2, 2015
CTAD 2015 presentation on the application of SNP profiling to risk stratification in Alzheimer’s disease
Sep 15, 2015
Cytox CEO keynote speaker at UKTI thought leadership conference on dementia
Jul 20, 2015
Cytox and Affymetrix form strategic partnership to develop and commercialize blood-based genetic assay for Alzheimer’s disease risk assessment
Jul 14, 2015
Cytox – The application of SNP profiling to risk stratification in Alzheimer’s disease to be presented at AAIC 2015
Apr 20, 2015
Cytox awarded Innovate UK funding for stratification of neurodegenerative diseases